The company started a phase 2 trial studying VK2735 in obese patients back in September 2023 with the purpose of assessing the safety and efficacy of the once weekly subcutaneous drug
In the hypoxic microenvironment of solid tumors (253), HIF-1 biaxially induces resistance to copper-dependent cell death by upregulating pyruvate dehydrogenase kinase 1/3-mediated degradation of DLAT and promoting MT2A-mediated chelation of free copper
Promotes Fat Oxidation and Metabolic Flexibility By combining incretin signaling with glucagon-mediated pathways, retatrutide is studied for its ability to promote fat oxidation while preserving metabolic balance
Differences in food consumption between patients with Hashimoto's thyroiditis and healthy individuals
Although a PBM may list the drug on their formulary, the decision to provide coverage for the medication still falls upon the plan sponsor. In addition, payers should: Review PBM formulary and utilization management systems to ensure that only clinically eligible patients get the drugs Negotiate lowest-net-cost PBM formulary changes to obtain the medications at the lowest prices Contract with a PBM that approves of manufacturer copay cards for non-specialty drugs, which can lower the cost burden on the payer The weight loss potential cannot be easily dismissed on either a clinical or financial basis, according to the guide
